Details of the Drug Reposition

General Information of This Drug (ID: DMAEYR5)

Drug Name
BMX-001   DMAEYR5
Synonyms
Bmx-001; UNII-MIJ02RO47F; MIJ02RO47F; Manganese(5+), ((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, chloride (1:5), (sp-4-1)-; 1379783-91-1
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Head and neck cancer DISBPSQZ 2D42 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioma DIS5RPEH 2A00.0 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04607642) Trial of BMX-001 or Placebo in Head and Neck Cancer Patients. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)